Skip to main content
S&P 5007,562.96-0.30%DOW51,663.08-0.83%NASDAQ26,015.57+0.13%BTC$75,791.00+0.23%ETH$2,402.19+0.32%GOLD$4,342.30+0.22%OIL$102.35-3.29%
Smart Investors Daily
MB

NASDAQ · MBX

MBX Biosciences, Inc. Common Stock

Healthcare · Biotechnology

$61.08

Down-$0.86 (-1.41%)

Updated Sep 16, 2026, 6:56 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
954.72M
P/E ratio
-12.07
Dividend yield
0.00%
52-week range
$9.64 – $72.64
Volume
652.59K
Avg. volume
1.44M

Price performance

MBX price history

1M range · 20 trading sessions · Daily adjusted prices

MBX closed at $61.08 after 20 trading sessions, down 8.18% for the selected period.

Last close
$61.08
Period change
-8.18%
Period low
$59.02
Period high
$68.62
Daily close
View OHLC price history
MBX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$58.79$61.195$58.394$61.08652.59K
Sep 14, 2026$59.35$60.22$58.87$59.49323.68K
Sep 11, 2026$61.75$61.94$58.42$59.02306.21K
Sep 10, 2026$62.43$63.015$60.65$60.94457.27K
Sep 9, 2026$63.29$64.04$61.285$62.91315.69K
Sep 8, 2026$60.85$64.17$60.66$62.99266.22K
Sep 4, 2026$61.00$62.73$60.595$61.72271.78K
Sep 3, 2026$60.90$62.6099$59.84$61.42292.66K
Sep 2, 2026$61.40$62.45$58.80$60.89352.29K
Sep 1, 2026$61.42$62.88$60.215$60.93416.09K
Aug 31, 2026$62.25$63.04$59.47$61.60518.3K
Aug 28, 2026$66.14$66.14$62.99$63.00307.65K
Aug 27, 2026$66.73$66.90$64.50$66.39263.55K
Aug 26, 2026$68.56$68.83$66.27$66.76214.78K
Aug 25, 2026$67.64$69.50$67.64$68.62274.03K
Aug 24, 2026$66.23$67.155$64.00$66.39531.07K
Aug 21, 2026$67.86$67.86$65.5908$66.33466.65K
Aug 20, 2026$67.00$68.49$65.3956$66.35422.51K
Aug 19, 2026$67.53$68.76$65.25$68.40562.35K
Aug 18, 2026$66.40$69.05$65.795$66.52560.74K

Latest MBX news

The latest Smart Investors Daily articles mentioning MBX.

Stock researchCompany · Overview

MBX research

Overview

Company profile and research snapshot.

Company profile

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$28.00
Implied upside
—
Analysts
—
MBX recent ratings
DateFirmRatingTarget
Aug 21, 2026JP MorganOverweight—
Aug 10, 2026Truist SecuritiesBuy—
Jul 29, 2026MizuhoOutperform—
May 12, 2026BarclaysOverweight—
May 12, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

MBX Biosciences to Participate in Upcoming Investor Conferences

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor confer

Yahoo · Sep 8, 2026

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

CARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Jeff Held, J.D., as Chief Legal Officer. Mr. Held brings more than three decades of legal, compliance and executive leadership experience across biotechnology, l

Yahoo · Aug 27, 2026

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support once-weekly canvuparatide’s potential as a best-in-class PTH replacement therapy CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By